Company: HURA
Filing Date: 2025-02-07
Form Type: S-4
Source: 0001193125-25-022803
Chunk: 653

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-02-07
Form: S-4
Chunk 653
---
 condensed combined balance sheet as of September 30, 2024 assumes that the Mergers occurred on that date, any advances loaned by TuHURA to Kineta under the CTF Agreement would result in a net zero impact to the financial statements of TuHURA. The unaudited pro forma condensed combined balance sheet as of September 30, 2024 includes adjustments to give pro forma effect for both the cash loaned by TuHURA and received by Kineta subsequent to September 30, 2024, to illustrate the funding provided by TuHURA under the CTF Agreement (refer to Adjustment H).

BRelating to the Mergers, the $300,000 of additional financing that is presented as both a cash inflow (for Kineta) and cash outflow (for Legacy TuHURA), the payment reflects the nonrefundable extension cash payments made under the Exclusivity Agreement, to extend the Exclusivity Period that would have expired on October 1, 2024 unless renewal payments were made after such date.

On October 4, 2024, Legacy TuHURA paid Kineta $150,000 as an additional exclusivity payment for the first Renewal Period. On October 15, 2024, Legacy TuHURA paid Kineta $150,000 as an**

<div align='center'>**424

NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION**</div>

**additional exclusivity payment for the second Renewal Period. The unaudited pro forma condensed combined balance sheet as of September 30, 2024 includes these adjustments to give pro forma effect for both the cash loaned by Legacy TuHURA and received by Kineta subsequent to September 30, 2024, to illustrate the funding provided by TuHURA under the Exclusivity Agreement and also given that all exclusivity and associated renewal payments were included in the Merger Agreement between the parties as being credited against the cash component of the Merger Consideration to be paid to Kineta stockholders in the Mergers (refer to Adjustment H).

CRelating to the Mergers, to record proceeds received of $35 million, net of equity issuance costs of $2.5 million (comprised of an estimated $2.1 million of placement fees and an additional $0.4 million in legal fees), following the issuance, through a Concurrent Investment to be consummated prior to the Closing of the M